To determine whether long-term tumor-specific protective immunity developed after treatment with IL-21 + IL-2, mice surviving tumor free for 150 days were subsequently rechallenged subcutaneously with 5 × 105 B16F10 tumor cells or 5 × 104 3LL tumor cells. The gene discussed is IL21; the disease is neoplasm.